Published in Am J Physiol Heart Circ Physiol on November 30, 2012
Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling. Biochem Pharmacol (2015) 0.87
AICAR-dependent AMPK activation improves scar formation in the aged heart in a murine model of reperfused myocardial infarction. J Mol Cell Cardiol (2013) 0.86
Stretch-sensitive down-regulation of the miR-144/451 cluster in vascular smooth muscle and its role in AMP-activated protein kinase signaling. PLoS One (2013) 0.86
PVP formulated fullerene (C60) increases Rho-kinase dependent vascular tissue contractility in pregnant Sprague Dawley rats. Reprod Toxicol (2014) 0.86
Perivascular fat, AMP-activated protein kinase and vascular diseases. Br J Pharmacol (2014) 0.86
Experimental Rat and Mouse Carotid Artery Surgery: Injury & Remodeling Studies. ISRN Minim Invasive Surg (2013) 0.82
Sodium tanshinone IIA silate inhibits high glucose-induced vascular smooth muscle cell proliferation and migration through activation of AMP-activated protein kinase. PLoS One (2014) 0.82
Adenosine monophosphate-activated protein kinase-α2 deficiency promotes vascular smooth muscle cell migration via S-phase kinase-associated protein 2 upregulation and E-cadherin downregulation. Arterioscler Thromb Vasc Biol (2013) 0.81
Complement anaphylatoxin C4a inhibits C5a-induced neointima formation following arterial injury. Mol Med Rep (2014) 0.80
Regulation of hyaluronan synthesis in vascular diseases and diabetes. J Diabetes Res (2015) 0.79
Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. Oncotarget (2015) 0.77
Anti-hypertensive Herbs and their Mechanisms of Action: Part I. Front Pharmacol (2016) 0.76
AMP-activated protein kinase inhibits transforming growth factor-β-mediated vascular smooth muscle cell growth: implications for a Smad-3-dependent mechanism. Am J Physiol Heart Circ Physiol (2015) 0.76
Comparison of gene expression profiles and related pathways in chronic thromboembolic pulmonary hypertension. Int J Mol Med (2013) 0.76
Microvesicles Derived from Inflammation-Challenged Endothelial Cells Modulate Vascular Smooth Muscle Cell Functions. Front Physiol (2017) 0.75
AdipoRon, an adiponectin receptor agonist, attenuates PDGF-induced VSMC proliferation through inhibition of mTOR signaling independent of AMPK: Implications toward suppression of neointimal hyperplasia. Pharmacol Res (2017) 0.75
Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation. Cell Signal (2016) 0.75
The hypotensive effect of acute and chronic AMP-activated protein kinase activation in normal and hyperlipidemic mice. Vascul Pharmacol (2015) 0.75
Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev (2004) 16.52
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol (2007) 15.30
Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 9.40
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol (2011) 6.83
Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility. Cell (2002) 6.80
AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev (2011) 5.26
Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J (2007) 4.48
Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab (2010) 4.14
Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein. Proc Natl Acad Sci U S A (2001) 3.57
Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J Biol Chem (1998) 3.53
Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci (2010) 3.17
Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol (2003) 3.15
Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J Biol Chem (2005) 2.88
Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem (2006) 2.69
Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem (2007) 2.54
Identification of phosphorylation sites in AMP-activated protein kinase (AMPK) for upstream AMPK kinases and study of their roles by site-directed mutagenesis. J Biol Chem (2003) 2.45
Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol (2003) 2.17
Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res (2005) 2.15
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility. Curr Opin Cell Biol (2009) 1.99
Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem Biol (2008) 1.93
AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation (2004) 1.85
Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res (2005) 1.76
The bundling activity of vasodilator-stimulated phosphoprotein is required for filopodium formation. Proc Natl Acad Sci U S A (2006) 1.72
From the membrane to the nucleus and back again: bifunctional focal adhesion proteins. Curr Opin Cell Biol (2006) 1.47
Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. Atherosclerosis (2001) 1.41
Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J (1993) 1.38
The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med (2009) 1.35
Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2004) 1.31
AMP-activated protein kinase impairs endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated phosphoprotein. J Biol Chem (2006) 1.23
Activation of AMP kinase alpha1 subunit induces aortic vasorelaxation in mice. J Physiol (2007) 1.19
Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci (2009) 1.19
YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun (2000) 1.19
AMPKα2 deletion exacerbates neointima formation by upregulating Skp2 in vascular smooth muscle cells. Circ Res (2011) 1.15
Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol (1985) (2004) 1.14
Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol (2005) 1.14
Rat carotid artery balloon injury model. Methods Mol Med (2007) 1.11
Interaction of paxillin with poly(A)-binding protein 1 and its role in focal adhesion turnover and cell migration. Mol Cell Biol (2005) 1.08
YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun (2002) 1.02
Plasmin potentiates induction of nitric oxide synthesis by interleukin-1 beta in vascular smooth muscle cells. Am J Physiol (1993) 1.01
Regulation of cGMP-dependent protein kinase expression by soluble guanylyl cyclase in vascular smooth muscle cells. J Biol Chem (2004) 1.00
Role of extracellular matrix in vascular remodeling of hypertension. Curr Opin Nephrol Hypertens (2010) 0.98
AMPK and vasculoprotection. Pharmacol Ther (2010) 0.97
Histological and morphometric analyses for rat carotid balloon injury model. Methods Mol Med (2007) 0.97
AMP-activated protein kinase induces actin cytoskeleton reorganization in epithelial cells. Biochem Biophys Res Commun (2010) 0.97
Neointima formation after acute vascular injury. Role of counteradhesive extracellular matrix proteins. Tex Heart Inst J (1994) 0.96
AICAR induces cyclooxygenase-2 expression through AMP-activated protein kinase-transforming growth factor-beta-activated kinase 1-p38 mitogen-activated protein kinase signaling pathway. Biochem Pharmacol (2010) 0.95
The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J Pharmacol Exp Ther (2011) 0.94
Structural basis for compound C inhibition of the human AMP-activated protein kinase α2 subunit kinase domain. Acta Crystallogr D Biol Crystallogr (2011) 0.94
Cordycepin suppresses TNF-alpha-induced invasion, migration and matrix metalloproteinase-9 expression in human bladder cancer cells. Phytother Res (2010) 0.94
Local administration of carbon monoxide inhibits neointima formation in balloon injured rat carotid arteries. Cell Mol Biol (Noisy-le-grand) (2005) 0.92
Activation of AMP-activated protein kinase inhibits the proliferation of human endothelial cells. J Pharmacol Exp Ther (2012) 0.91
Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. Clin Sci (Lond) (2011) 0.89
AMP-activated protein kinase activator AICAR acutely lowers blood pressure and relaxes isolated resistance arteries of hypertensive rats. J Hypertens (2012) 0.86
Aspirin-induced AMP-activated protein kinase activation regulates the proliferation of vascular smooth muscle cells from spontaneously hypertensive rats. Biochem Biophys Res Commun (2011) 0.85
Adenoviral gene transfer of fortilin attenuates neointima formation through suppression of vascular smooth muscle cell proliferation and migration. Circulation (2003) 0.85
FRNK inhibition of focal adhesion kinase-dependent signaling and migration in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2010) 0.84
Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells. J Cardiovasc Pharmacol (2009) 0.83
Compound C inhibits vascular smooth muscle cell proliferation and migration in an AMP-activated protein kinase-independent fashion. J Pharmacol Exp Ther (2011) 0.83
Development of fluorescence-based selective assays for serine/threonine and tyrosine phosphatases. Comb Chem High Throughput Screen (2003) 0.82
The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf (2006) 1.20
Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol (2005) 1.14
Steroid receptor coactivator-3 is required for inhibition of neointima formation by estrogen. Circulation (2002) 1.14
Nitric oxide-generating hydrogels inhibit neointima formation. J Biomater Sci Polym Ed (2005) 1.09
Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther (2013) 1.00
Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler Thromb Vasc Biol (2009) 0.99
Inhibition of autocrine fibroblast growth factor signaling by the adenovirus-mediated expression of an antisense transgene or a dominant negative receptor in human glioma cells in vitro. Int J Oncol (2002) 0.96
The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J Pharmacol Exp Ther (2011) 0.94
Bilirubin inhibits neointima formation and vascular smooth muscle cell proliferation and migration. Front Pharmacol (2012) 0.93
Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother (2004) 0.88
YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells. Mol Pharmacol (2008) 0.86
Inhibition of vascular smooth muscle growth via signaling crosstalk between AMP-activated protein kinase and cAMP-dependent protein kinase. Front Physiol (2012) 0.83
Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells. J Cardiovasc Pharmacol (2009) 0.83
Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside. Curr Vasc Pharmacol (2007) 0.83
Experimental Rat and Mouse Carotid Artery Surgery: Injury & Remodeling Studies. ISRN Minim Invasive Surg (2013) 0.82
The dopamine D3 receptor knockout mouse mimics aging-related changes in autonomic function and cardiac fibrosis. PLoS One (2013) 0.82
Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. Atherosclerosis (2007) 0.80
The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects. J Cardiovasc Pharmacol Ther (2009) 0.80
Control of vascular smooth muscle cell growth by connexin 43. Front Physiol (2012) 0.80
Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. Cardiovasc Hematol Agents Med Chem (2007) 0.79
Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway. J Neuropathol Exp Neurol (2002) 0.79
Rosuvastatin-warfarin drug interaction. Lancet (2004) 0.77
SHaRe: advancing the goal of effective treatment for cardiomyopathy. Eur Heart J (2015) 0.75